Bioretec Completes Change Negotiations
Bioretec Ltd has recently concluded its change negotiations aimed at enhancing the company’s production and marketing operations. The negotiations, initiated in accordance with Finnish labor laws, were designed to streamline operations to bolster competitiveness and overall profitability.
Negotiation Details
The negotiations commenced on November 12, 2025, and concluded on December 4, 2025. Initially, the company anticipated that up to eight employees might be affected by these changes. Ultimately, decisions were made to terminate the employment of two individuals while five production staff faced temporary layoffs. Additionally, the role of one employee is undergoing significant adjustments as a result of the reorganization.
Cost Savings from Restructuring
Bioretec expects that these negotiations will lead to annual cost savings in the vicinity of EUR 0.4 million. The discussions involved 15 employees from the company’s operations in Finland, emphasizing Bioretec's commitment to organizational efficiency.
Future Steps in Commercialization
In a strategy to enhance market presence, Bioretec is also reviewing its commercialization strategies alongside its product development pipeline. Updates regarding this strategy are anticipated to be shared with stakeholders by the end of 2025.
About Bioretec
Bioretec is positioned as a leading medical device company in Finland, innovating in the field of orthopedic care by developing entirely biodegradable implant technologies. It has crafted a reputation for excellence by integrating advanced biological interfaces in active implants, facilitating enhanced bone growth and accelerated healing processes following orthopedic surgeries. Bioretec’s innovative products are in use across approximately 40 global markets.
Product Innovations
One of the notable product lines from Bioretec is Activa, which includes fully bioabsorbable orthopedic implants engineered from a unique self-reinforced PLGA polymer. These implants provide secure fixation through innovative designs while naturally degrading over about two years, effectively negating the necessity for invasive removal surgeries and fostering optimal bone regeneration. The Activa range holds CE marks and FDA clearances for various indications applicable to both adult and pediatric patients.
New Innovations in Orthopedic Technology
Moreover, Bioretec has proudly introduced the RemeOs™ product line, which showcases a robust magnesium alloy and hybrid composite. This line represents a breakthrough in absorbable materials that promises to enhance surgical outcomes. RemeOs implants integrate with the body by being absorbed and replaced by bone, thus removing the need for removal surgery and aiding in the healing of fractures. The U.S. market granted approval for the first RemeOs product back in March 2023, with Europe following suit by awarding CE mark approval in January 2025.
Shaping the Future of Orthopedic Treatment
With its advancements in next-generation implant technology like RemeOs, Bioretec is endeavoring to redefine orthopedic treatment, translating into more effective, patient-friendly solutions. The organization’s commitment to fostering innovative healing methods remains steadfast.
Further Inquiries
For more information, contact Sarah van Hellenberg Hubar-Fisher, CEO, at +31 6 1544 8736.
Frequently Asked Questions
What prompted the change negotiations at Bioretec?
The negotiations aimed to streamline operations and improve the company's competitiveness and profitability.
What financial impact is expected from the restructuring?
Bioretec expects to achieve annual cost savings of approximately EUR 0.4 million from this restructuring process.
How many employees were affected by the negotiations?
Fifteen employees were involved in the negotiations, resulting in two terminations and five temporary layoffs.
What innovations is Bioretec working on?
Bioretec is advancing its product lines, notably Activa and RemeOs™, focusing on biodegradable and bioabsorbable implants.
When can we expect Bioretec's update on its commercialization strategy?
Bioretec plans to share an update regarding its commercialization strategy by the end of 2025.
